Mr. W. is a 66 year old man. Six years ago he w/as diagnosed with a moderately differentiated, localized prostate cancer (PCa) when he presented for a routine physical exam and was found to have a prostate specific antigen (PSA) blood test of 5.2. Digital rectal exam revealed no abnormalities but prostate ultrasound and biopsy revealed a Gleason 4+3 = 7 cancer in 2/12 biopsy cores (clinical stage TIcNxMx). Because Mr. W. was in otherwise excellent health, he chose to undergo a radical retro pubic prostatectomy and his prostate was removed. All of his lymph nodes were negative for cancer. He was considered to be cured of his disease. One year ago, Mr. W.'s PSA became detectable and he now has 3 lesions present on bone scan. He has metastatic prostate cancer, now incurable. Each year, approximately 40,000 men who "should" have been cured of their prostate cancer by surgery or radiation therapy present with incurable metastatic disease that will manifest itself as metastatic lesions in the bone, usually years after primary treatment. The only explanation for this is that disseminated tumor cells (DTCs) are present in the bone microenvironment before surgery or radiation eradicated the primary tumor. Clearly the ability of DTCs to proliferate, undergo apoptosis or become dormant must occur soon after the initial arrest of circulating tumor cells (CTCs) in the marrow. Unquestionably, a greater understanding of the molecular events that regulate a DTCs ability to become, and remain dormant over long periods is crucial to define new therapeutic strategies to combat disease progression. How these cells traffic to the bone (Project 1), become dormant (Project 2), and then ultimately begin to proliferate (Project 3) is the subject of this TMEN application. The proposed TMEN is composed of three highly interactive and complementary projects that are supported by a Human Sample Acquisition Core (HSAC). Ultimately this work will lead to defining new therapeutic strategies to combat PCa skeletal metastases. The findings generated by this program will lead to a significant impact on the health and well being of men with PCa. The global hypothesis Is that DTCs target the hematopoietic stem cell (HSC) niche during metastasis. Once In the niche the niche regulates dormancy of DTCs. When DTCs are able to overcome the growth regulatory effects of the HSC niche, metastatic foci develop.
This TMEN focuses on fundamental mechanisms related to tumor cell dormancy of PCa bone metastasis. We are confident that our observations are relevant to a more complete understanding prostate cancer skeletal disease. That new insights derived from these studies will lead to the development of innovative strategies to minimize the morbidity and mortality associated with bone metastatic prostate cancer.
|Jung, Younghun; Wang, Jingcheng; Lee, Eunsohl et al. (2015) Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res 13:197-207|
|Cordeiro-Spinetti, Eric; Taichman, Russell S; Balduino, Alex (2015) The bone marrow endosteal niche: how far from the surface? J Cell Biochem 116:11-Jun|
|Roca, Hernan; Pande, Manjusha; Huo, Jeffrey S et al. (2014) A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial - mesenchymal cell reprogramming and cancer progression. BMC Syst Biol 8:29|
|Axelrod, Haley; Pienta, Kenneth J (2014) Axl as a mediator of cellular growth and survival. Oncotarget 5:8818-52|
|Yumoto, Kenji; Berry, Janice E; Taichman, Russell S et al. (2014) A novel method for monitoring tumor proliferation in vivo using fluorescent dye DiD. Cytometry A 85:548-55|
|Yumoto, Kenji; Eber, Matthew R; Berry, Janice E et al. (2014) Molecular pathways: niches in metastatic dormancy. Clin Cancer Res 20:3384-9|
|Yang, Kimberline R; Mooney, Steven M; Zarif, Jelani C et al. (2014) Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering. J Cell Biochem 115:1478-85|
|Wan, Liling; Hu, Guohong; Wei, Yong et al. (2014) Genetic ablation of metadherin inhibits autochthonous prostate cancer progression and metastasis. Cancer Res 74:5336-47|
|Shiozawa, Yusuke; McGee, Samantha; Pienta, Michael J et al. (2013) Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. J Cell Biochem 114:2471-8|
|Taichman, Russell S; Patel, Lalit R; Bedenis, Rachel et al. (2013) GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One 8:e61873|
Showing the most recent 10 out of 18 publications